Clinical trial • Cardiology
Bisoprolol fumarate, hydrochlorothiazide for Idiopathic ventricular fibrillation | Out-of-hospital cardiac arrest (unexplained cardiac arrest)
Clinical trial of Bisoprolol fumarate, hydrochlorothiazide for Idiopathic ventricular fibrillation | Out-of-hospital cardiac arrest (unexplained cardiac a…
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Idiopathic ventricular fibrillation | Out-of-hospital cardiac arrest (unexplained cardiac arrest)
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 30-09-2024
- First CTIS Authorization Date
- 23-10-2024
Trial design
Randomised trial across 2 sites in Denmark.
- Randomised
- Yes
- Target Sample Size
- 218
- Trial Duration For Participant
- 1095
Eligibility
Recruits 218 adults.
Inclusion criteria
- {"criterion_text":"- Unexplained cardiac arrest survivors aged 18 or older\n- All patients surviving a cardiac arrest will receive a minimum diagnostic work-up consisting of an ECG, a Holter monitor during admission, an echocardiography, consecutive blood samples during the first 24 hours, and a coronary angiography or a cardiac CT-scan. Further evaluation with SAECG, stress-ECG, Cardiac MRI, and Sodium-channel blocker testing will be performed subsequently\n- All patients will have an ICD implanted"}
Exclusion criteria
- {"criterion_text":"- Age under 18 years\n- Explained cardiac arrest"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Endpoint will be one of the following 1) first appropriate therapy by ICD, 2) aborted shock or non-sustained VF, where the treating physician opts XML File Identifier: kg77bYwzweR7n2lb9bLtT2kXLeo= Page 25/34 for a change in medication, or 3) 3 years after randomizationdischarge, whichever comes first.","definition_or_measurement_approach":"Measured by ICD events (first appropriate therapy by ICD), aborted shock or non-sustained ventricular fibrillation leading to change in medication, or by time (3 years after randomization/discharge)."}
Secondary endpoints
- {"endpoint_text":"- Quality of life after 1 year","definition_or_measurement_approach":"Not specified in the record."}
Recruitment
- Planned Sample Size
- 218
- Recruitment Window Months
- 115
- Consent Approach
- Not specified in the record; subject information and informed consent form documents are listed (L1_SIS and ICF documents present) but content/details (who provides consent, age-specific documents, languages) are not available in the provided JSON.
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 218
Denmark
- Earliest CTIS Part Ii Submission Date
- 11-10-2024
- Latest Decision Or Authorization Date
- 23-10-2024
- Processing Time Days
- 12
- Number Of Sites
- 2
- Number Of Participants
- 218
Sites
- Site Name
- Rigshospitalet
- Department Name
- Cardiology
- Principal Investigator Name
- Bo Winkel
- Principal Investigator Email
- bo.winkel@regionh.dk
- Contact Person Name
- Bo Winkel
- Contact Person Email
- bo.winkel@regionh.dk
- Site Name
- Odense University Hospital
- Department Name
- Cardiology
- Principal Investigator Name
- Finn Henriksen
- Principal Investigator Email
- fhenriksen@health.sdu.dk
- Contact Person Name
- Finn Henriksen
- Contact Person Email
- fhenriksen@health.sdu.dk
Sponsor
Primary sponsor
- Full Name
- Rigshospitalet
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"Sponsor duties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"Denmark","full_name":"Odense University Hospital","duties_or_roles":"Sponsor duties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- BISOPROLOL
- Active Substance
- Bisoprolol fumarate, hydrochlorothiazide
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Maximum Dose
- 2.50 mg
- Investigational Product Name
- METOPROLOL
- Active Substance
- Metoprolol
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Maximum Dose
- 50 mg
- Investigational Product Name
- ATENOLOL
- Active Substance
- Atenolol, Chlortalidone
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Maximum Dose
- 25 mg
- Investigational Product Name
- NADOLOL
- Active Substance
- Nadolol
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Maximum Dose
- 40 mg
- Investigational Product Name
- PROPRANOLOL
- Active Substance
- Propranolol hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Maximum Dose
- 80 mg
Related trials
Other published trials that may interest you.
- METHYLPREDNISOLONE for Fulminant myocarditis
- PELACARSEN for Cardiovascular disease | Arteriosclerotic cardiovascular disease
- clopidogrel for Acute coronary syndrome | Cardiovascular diseases
- APIXABAN for Venous thromboembolism
- SOTAGLIFLOZIN for Obstructive hypertrophic cardiomyopathy | Non-obstructive hypertrophic cardiomyopathy